JPMorgan raises target for Qiagen stock from USD 50 to USD 55

Published on 10/20/2026 at 10:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Qiagen stock costs EUR 41.66 on October 20, 2026, 0.99 percent above the Xetra close. Q2 revenue was USD 535.04 million.

Analyst action and operating figures

JPMorgan raised its Qiagen target from USD 50 to USD 55 on October 14, 2026.
Qiagen reported USD 535.04 million in second-quarter revenue and USD 0.62 in adjusted earnings per share for 2026.
Qiagen stock trades at EUR 41.66 at 10:35 a.m. CEST at Lang & Schwarz on October 20, 2026, 0.99 percent above the Xetra close of October 19, 2026.

Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte, klinisches Laborlicht — Qiagen N.V. (NL0012169213) Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte im klinischen Labor, Illustration mit AI erstellt.

Qiagen stock (ISIN NL0015002SN0) trades at EUR 41.66 at Lang & Schwarz on October 20, 2026 at 10:35 a.m. CEST, up EUR 0.41, or 0.99 percent, versus the Xetra close of October 19, 2026 at EUR 41.25. MarketBeat reported on October 14, 2026 that JPMorgan raised its Qiagen target from USD 50 to USD 55 while maintaining an overweight rating. The target revision gives the analyst action more weight than the sub-1 percent daily move.

JPMorgan lifts the valuation marker

The higher target followed a Q3 earnings preview, according to Markets Insider. JPMorgan kept its overweight view, placing the new USD 55 target above the latest USD 46.55 NYSE reference price on October 19, 2026. Qiagen also carries a broader valuation counterweight: MarketBeat reported a consensus target of USD 43.93 and an average Hold rating on October 14, 2026.

What does the target change mean?

The operating backdrop is steady rather than explosive. Qiagen reported second-quarter 2026 revenue of USD 535.04 million, compared with USD 527.50 million expected, and adjusted earnings per share of USD 0.62 against a USD 0.60 consensus, according to MarketBeat. The revenue comparison is the more cautious signal because the reported increase over expectations was paired with revenue growth of 0.2 percent from the comparable period.

Three dated Qiagen developments

On August 5, 2026, Qiagen reported second-quarter 2026 net sales of USD 535 million and reaffirmed full-year adjusted diluted earnings per share of at least USD 2.43 in a filing carried by the AFM. On September 28, 2026, Qiagen announced FDA clearance for a new QIAstat-Dx bloodstream infection panel, as reported by FinanzNachrichten. On October 13, 2026, the company opened its Global TB Clinical and Educational Summit, which ran through October 16, 2026, according to the QIAGEN release.

Stock stays below its yearly high

The euro quotation sits inside a 52-week range of EUR 27.56 to EUR 47.60. Qiagen therefore remains below its yearly high while the latest quarterly figures support the case for a measured valuation discussion rather than a purely technical move.

Qiagen stock price and outlook

Qiagen stock was trading at EUR 41.66 at Lang & Schwarz on October 20, 2026 at 10:35 a.m. CEST, 0.99 percent above the Xetra close of October 19, 2026 at EUR 41.25.

The further course of trading is shown by the continuously updated real-time quote of Qiagen stock.